Veracyte a molecular diagnostics company pioneering the emerging field of molecular cytology, and Genzyme, a Sanofi company (NYSE: SNY), today announced that the New York State Department of Health has issued a license enabling Veracyte's Afirma® Gene Exp

"We are delighted that the Afirma Gene Expression Classifier will now be available to physicians and their patients in New York State and that Memorial Sloan-Kettering is among the first in the state to offer our test," said Bonnie Anderson, Veracyte's cofounder and chief executive officer. "These milestones underscore the clinical need for and strength of the clinical data behind our test. Our goal is to help identify patients whose thyroid nodules are actually benign so that they may avoid unnecessary, invasive surgery."